WDNA vs XBI: Grades, Fees and Holdings Compared

WisdomTree BioRevolution Fund

WDNACCboe

State Street SPDR S&P Biotech ETF

XBIANYSE Arca

Overlap

43.0%by weight

Expense ratio

XBI −0.10pt a year

WDNA0.45%XBI0.35%

Avg volume · 30D

XBI 3469.8×the volume

WDNA2.58KXBI8.95M

5Y return · a year

XBI +4.6pt

WDNA+0.1%XBI+4.7%

WDNA vs XBI Performance

Oct 29, 2021 – Oct 30, 2026

+0.4%WDNA+25.8%XBI

Expense ratio: WDNA 0.45%; XBI 0.35%, better
Fund size: WDNA $5M; XBI $10.8B
1Y total return: WDNA +46.6%, better; XBI +39.0%
Yield (12M): WDNA 3.21%, better; XBI 0.35%
Holdings: WDNA 89; XBI 164
Avg volume (30D): WDNA 2.58K sh; XBI 8.95M sh, better
NAV per share: WDNA $24.06; XBI $157.82
52W range

ETF.net Grade

Pillar letters and Scores for WDNA, XBI, with each pillar’s weight
Pillar	WDNA	XBI
Cost30% weight	B56	A81Higher
Mission25% weight	B65	A85Higher
Risk15% weight	C42	C47Higher
Tradability15% weight	F3	A99Higher
Holdings10% weight	A80	A88Higher
Durability5% weight	F20	A89Higher

Rank among Biotech & Genomics funds

How we build Categories ›

Same Category. WDNA and XBI are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds

See all 17 ›

XBI ranks 1st and WDNA 11th of 17 funds in the Biotech & Genomics Category.

Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
Rank 11CGNMXCorgi Genomics & Precision Medicine ETFScore 40
Rank 11CWDNAWisdomTree BioRevolution FundScore 40
Rank 13DHELXFranklin Genomic Advancements ETFScore 39

Our read on each fund

ETF.net Research

WDNACWisdomTree BioRevolution Fund

XBIAState Street SPDR S&P Biotech ETF

In short

WDNA Most biotech funds stop at drug developers. WDNA follows biology out of the clinic and into food, materials and industrial chemistry, tracking a WisdomTree index shaped with futurist Jamie Metzl.

XBI Biotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

WDNA The Fund seeks to track the WisdomTree BioRevolution Index before fees and expenses. It uses a passive representative-sampling approach to gain global equity exposure to companies expected to be significantly transformed by advances in genetics and biotechnology.

XBI The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

WDNA Wider map than a pipeline fund: the index sorts companies across human health, agriculture and food, materials/chemicals/energy, and biological machines and interfaces.wisdomtree.com
The 0.45% expense ratio sits under the median for genomics and biotech thematics, which is unusual for a niche with this much research behind the index.
Passive and global by design: roughly 100 listed names worldwide, sampled to track the WisdomTree BioRevolution Index rather than picked by a manager.wisdomtree.com

XBI Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

WDNA A small, thinly traded fund. Spreads can run wider than the category heavyweights, so the price you get may drift from the value of what you own.
For plain biotech exposure, bigger peers cost less: IBBQ at 0.19% and XBI at 0.35%. You pay WDNA's fee for the broader multi-sector definition.
The issuer flags the theme's own hazards: intense competition, fast product obsolescence, intellectual-property loss, and shifting government rules.wisdomtree.com

XBI Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.com nasdaqomx.com
Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

Full WDNA profile⁠

Full XBI profile⁠

WDNA vs XBI Holdings

How WDNA and XBI differ

Overlap by weight

43.0%

Shared holdings make up 63.1% of WDNA and 50.7% of XBI.

Level by level

Holdings51 in both43.0%
Countryby domicile90.3%
Sector4 Sectors91.2%
Asset classEquity100%

Sector

Sector weights in WDNA and XBI, widest gap first
Sector	More in WDNAMore in XBI	WDNA	XBI
Health Care	XBI +8.1 points	91.2%	99.3%
Materials	WDNA +5.4 points	5.4%	0.0%
Consumer Staples	WDNA +3.4 points	3.4%	0.0%
Financials	XBI +0.7 points	0.0%	0.7%

Country, concentration and asset class

Country by domicile

Country weights in WDNA and XBI, widest gap first
Country	More in WDNAMore in XBI	WDNA	XBI
United States	XBI +9.7 points	87.0%	96.7%
United Kingdom	WDNA +2.9 points	4.2%	1.3%
Denmark	WDNA +2.0 points	2.0%	0.0%
Germany	WDNA +1.8 points	1.8%	0.0%
Switzerland	WDNA +1.3 points	2.7%	1.4%
Netherlands	WDNA +0.7 points	1.2%	0.5%
Belgium	WDNA +0.6 points	0.6%	0.0%
Other countries (3)	WDNA +0.4 points	0.5%	0.1%

Concentration

Weight in the 10 largest Holdings

WDNA28.3%
XBI18.0%

Securities held

WDNA83
XBI163

Asset class

WDNA: Equity
XBI: Equity

Holdings

Only in WDNA32
In both51
Only in XBI112

Only in WDNA

32 securities, 36.9% of WDNA by weight

Eli Lilly & Co3.65%
Tempus Ai Inc3.40%
Thermo Fisher Scientific Inc2.47%
10X Genomics Inc-Class A2.17%
Darling Ingredients Inc1.65%
Astrazeneca Plc1.58%
Pfizer Inc1.49%
Vylor Inc1.47%
Bayer AG1.39%
Novozymes A/S1.32%
Novartis AG1.21%
Caris Life Sciences Inc1.19%
Structure Therapeutics Inc1.08%
Wave Life Sciences Inc0.99%
Rocket Pharmaceuticals Inc0.93%
Argenx Se - Adr0.88%
Repligen Corp0.83%
Danaher Corp0.80%
Arcturus Therapeutics Hlgs0.78%
Genmab A/S -Sp ADR0.75%
Biontech Se-ADR0.75%
Merck & Co Inc/NJ0.70%
Oxford Nanopore Technologies0.68%
Illumina Inc0.63%
Syensqo Sa0.60%
Qiagen N.v.0.54%
Verbio AG0.53%
Zoetis Inc0.52%
Nufarm Ltd/Australia0.51%
Genus Plc0.50%
Neuropace Inc0.47%
Green Plains Inc0.47%

Only in XBI

112 securities, 49.3% of XBI by weight

AbbVie Inc1.66%
Spyre Therapeutics Inc1.63%
Tg Therapeutics Inc1.52%
Alkermes PLC1.43%
Ptc Therapeutics Inc1.37%
Neurocrine Biosciences Inc1.35%
Incyte Corp1.33%
Kymera Therapeutics Inc1.27%
Kodiak Sciences Inc1.25%
Cytokinetics Inc1.23%
Erasca Inc1.22%
Cogent Biosciences Inc1.21%
Vaxcyte Inc1.21%
Madrigal Pharmaceuticals Inc1.13%
Dianthus Therapeutics Inc1.11%
Travere Therapeutics Inc1.10%
Rhythm Pharmaceuticals Inc1.07%
Mirum Pharmaceuticals Inc1.03%
Immunitybio Inc0.99%
Arcutis Biotherapeutics Inc0.94%
Relay Therapeutics Inc0.92%
Caredx Inc0.92%
Tango Therapeutics Inc0.89%
Celcuity Inc0.81%
Scholar Rock Holding Corp0.78%
Hyperliquid Strategies0.72%
Recursion Pharmaceuticals A0.68%
Immunovant Inc0.61%
Viridian Therapeutics Inc0.60%
Disc Medicine Inc0.58%
Denali Therapeutics Inc0.57%
Summit Therapeutics Inc0.57%
Biocryst Pharmaceuticals Inc0.57%
Sellas Life Sciences Group I0.56%
Sarepta Therapeutics Inc0.55%
Vera Therapeutics Inc0.54%
Palvella Therapeutics Inc0.53%
Adma Biologics Inc0.52%
Acadia Pharmaceuticals Inc0.50%
Novavax Inc0.47%
Vericel Corp0.46%
Replimune Group Inc0.42%
First Tracks Biotherapeu W/I0.38%
Arcus Biosciences Inc0.37%
Nektar Therapeutics0.37%
Precigen Inc0.37%
Syndax Pharmaceuticals Inc0.35%
Mineralys Therapeutics Inc0.30%
Anaptysbio Inc0.30%
Zenas Biopharma Inc0.29%

Weight gaps

All 51 Holdings in both funds, largest gap first.

Holding weights in WDNA and XBI, widest gap first
Holding	More in WDNAMore in XBI	WDNA	XBI
Immunome IncIMNM	WDNA +2.37 points	2.72%	0.35%
Stoke Therapeutics IncSTOK	WDNA +1.87 points	2.21%	0.34%
Twist Bioscience CorpTWST	WDNA +1.65 points	3.63%	1.98%
Natera IncNTRA	WDNA +1.15 points	3.04%	1.89%
Prime Medicine IncPRME	WDNA +1.08 points	1.26%	0.18%
Biogen Idec IncBIIB	XBI +0.86 points	0.84%	1.70%
Halozyme Therapeutics IncHALO	XBI +0.81 points	0.94%	1.75%
Xencor IncXNCR	WDNA +0.79 points	1.16%	0.37%
BioMarin Pharmaceutical IncBMRN	XBI +0.77 points	0.51%	1.28%
Regeneron Pharmaceuticals IncREGN	XBI +0.75 points	0.70%	1.45%
4D Molecular Therapeutics InFDMT	WDNA +0.74 points	0.89%	0.15%
Insmed IncINSM	XBI +0.70 points	0.54%	1.24%
Vir Biotechnology IncVIR	WDNA +0.68 points	0.97%	0.29%
Uniqure NVQURE	WDNA +0.66 points	1.16%	0.50%
Biohaven LtdBHVN	WDNA +0.64 points	1.23%	0.59%
ABSCI CorpABSI	WDNA +0.58 points	1.16%	0.58%
Nurix Therapeutics IncNRIX	WDNA +0.57 points	1.15%	0.58%
Cullinan Therapeutics IncCGEM	WDNA +0.57 points	0.75%	0.18%
Editas Medicine IncEDIT	WDNA +0.54 points	0.66%	0.12%
Cg Oncology IncCGON	WDNA +0.50 points	1.45%	0.95%
Agios Pharmaceuticals IncAGIO	WDNA +0.50 points	1.12%	0.62%
United Therapeutics CorpUTHR	WDNA +0.50 points	2.18%	1.68%
Dyne Therapeutics IncDYN	WDNA +0.49 points	1.21%	0.72%
Exelixis IncEXEL	XBI +0.49 points	1.14%	1.63%
Grail IncGRAL	XBI +0.49 points	1.02%	1.51%
Beam Therapeutics IncBEAM	WDNA +0.49 points	1.45%	0.96%
Moderna IncMRNA	WDNA +0.47 points	2.83%	2.36%
Intellia Therapeutics IncNTLA	WDNA +0.44 points	0.99%	0.55%
Iovance Biotherapeutics IncIOVA	XBI +0.40 points	0.64%	1.04%
Vertex Pharmaceuticals IncVRTX	WDNA +0.37 points	1.86%	1.49%
Protagonist Therapeutics IncPTGX	XBI +0.36 points	1.06%	1.42%
Ideaya Biosciences IncIDYA	WDNA +0.34 points	0.85%	0.51%
Ultragenyx Pharmaceutical IncRARE	XBI +0.33 points	0.50%	0.83%
Viking Therapeutics IncVKTX	XBI +0.32 points	0.58%	0.90%
Oruka Therapeutics IncORKA	XBI +0.32 points	1.20%	1.52%
Regenxbio IncRGNX	WDNA +0.32 points	0.46%	0.14%
Allogene Therapeutics IncALLO	WDNA +0.30 points	0.41%	0.11%
Roivant Sciences LtdROIV	WDNA +0.30 points	1.59%	1.29%
Revolution Medicines IncRVMD	WDNA +0.29 points	1.60%	1.31%
Isis Pharmaceuticals IncIONS	XBI +0.24 points	0.90%	1.14%
Celldex Therapeutics IncCLDX	WDNA +0.23 points	0.70%	0.47%
Alnylam Pharmaceuticals IncALNY	XBI +0.23 points	0.74%	0.97%
Geron CorpGERN	WDNA +0.18 points	0.35%	0.17%
Bridgebio Pharma IncBBIO	XBI +0.17 points	1.16%	1.33%
Krystal Biotech IncKRYS	WDNA +0.17 points	1.51%	1.34%
Praxis Precision Medicines IPRAX	XBI +0.16 points	1.04%	1.20%
Gilead Sciences IncGILD	WDNA +0.14 points	1.77%	1.63%
Veracyte IncVCYT	XBI +0.12 points	1.06%	1.18%
Arrowhead Pharmaceuticals IncARWR	XBI +0.10 points	0.95%	1.05%
Crispr Therapeutics AgCRSP	WDNA +0.07 points	1.50%	1.43%
Amgen IncAMGN	WDNA +0.06 points	1.75%	1.69%

All 99 WDNA holdings⁠All 165 XBI holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

WDNA vs XBI Cost

Overpaying WDNA vs XBI

$1,915

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

WDNA 0.45%
$9,041
XBI 0.35%
$7,126

Amount$10,000

Years30 years

Cost over time

WDNA 0.45%
XBI 0.35%
Overpaying

Year by year

Year	WDNA	XBI	Overpaying
10	$812	$634	$178
20	$3,128	$2,454	$674
30	$9,041	$7,126	$1,915

Expense ratio

0.45%WDNA
0.35%XBI, cheaper

XBI0.35%WDNA0.45%

0.19%0.75%

Middle half of Biotech & Genomics funds
Median 0.47%

XBI 3rd cheapest of 17 funds

WDNA 7th cheapest of 17 funds

WDNA vs XBI Dividends

Last 12 months to Oct 30, 2026

Yield (12M): WDNA 3.21%, better; XBI 0.35%
Payout (12M): WDNA $0.77; XBI $0.54
Last payment: WDNA $0.77; XBI $0.14
Ex-dividend: WDNA Dec 26, 2025; XBI Jun 22, 2026
Paid on: WDNA Dec 30, 2025; XBI Jun 24, 2026
Frequency: WDNA Annual; XBI Twice a year

Distribution history

Per share, 2017 to 2026, same scale for both

WDNAAnnual · 5 paymentsAll WDNA payments⁠

XBITwice a year · 24 paymentsAll XBI payments⁠

WDNA vs XBI Risk

Fall from peak · 5 years

WDNA
XBI

Risk facts

VolatilityStd dev, 3 years: WDNA 24.6%, betterXBI 24.8%
Return per unit of riskSharpe ratio, 3 years: WDNA 0.79XBI 1.11, better
Worst fallMax drawdown, 5 years: WDNA −56.8%XBI −53.2%, better
Market sensitivityBeta, 5 years: WDNA 1.26XBI 1.10; Market = 1

WDNA and XBI in the news

All news⁠

Deep Dive
Moderna fell 18% on cancer-vaccine data, and genomics ETFs fell 4%
Oct 23, 2026XBI
Top Movers
iShares MSCI Indonesia ETF EIDO jumps 7.2% as Jakarta rebounds
Oct 20, 2026XBI
Closing Bell
Investors rotate out of tech as health care hits a record; Dow gains 1%
Oct 20, 2026XBI
Top Movers
Constellation rose 12% on Google's nuclear deal, and genomics funds sank
Oct 6, 2026XBI
Top Movers
Fair Isaac fell 26.5% after a rival score joined Fannie and Freddie's fee grid
Sep 29, 2026XBI
News
AstraZeneca agrees to invest $2 billion in Summit, without the drug rights
Sep 28, 2026XBI

Popular comparisons

WDNACvsIBBQA
WisdomTree BioRevolution Fund · Invesco Nasdaq Biotechnology ETF
Expense ratio
0.45% · 0.19%
Category
XBIAvsIBBQA
State Street SPDR S&P Biotech ETF · Invesco Nasdaq Biotechnology ETF
Expense ratio
0.35% · 0.19%
Category
WDNACvsIBBA
WisdomTree BioRevolution Fund · iShares Biotechnology ETF
Expense ratio
0.45% · 0.44%
Category
XBIAvsIBBA
State Street SPDR S&P Biotech ETF · iShares Biotechnology ETF
Expense ratio
0.35% · 0.44%
Category
WDNACvsBBPA
WisdomTree BioRevolution Fund · Virtus Biotech ETF
Expense ratio
0.45% · 0.34%
Category
XBIAvsBBPA
State Street SPDR S&P Biotech ETF · Virtus Biotech ETF
Expense ratio
0.35% · 0.34%
Category